Hot Features
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascul... Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 1221 | 1.0E-6 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 5284 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 4602 | 3.31E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 9285 | 1.47E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0005 | 1.0E-6 | 9099 | 4.67E-6 | CS |
| 156 | -0.012099 | -99.9917355372 | 0.0121 | 0.0425 | 1.0E-6 | 202998 | 0.01556573 | CS |
| 260 | -0.012099 | -99.9917355372 | 0.0121 | 0.0425 | 1.0E-6 | 202998 | 0.01556573 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.